Pharmaceutical

Xaluritamig by Amgen for Prostate Cancer: Likelihood of Approval

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer.

Dec 31, 2024 - 06:00
Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer.
Read the original article

Tags:

Previous Article

LXE-408 by Novartis for Chagas Disease (American Trypanosomiasis): Likelihood of...

Next Article

NVP-1805R2 by NVP Healthcare for Unspecified Cardiovascular Disorders: Likelihoo...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA warns of rare hypersensitivity reaction due to antiseizure drugs

FDA warns of rare hypersensitivity reaction due to anti...

Dec 30, 2023

J&J asserts its place in atopic dermatitis space with Yellow Jersey acquisition

J&J asserts its place in atopic dermatitis space with Y...

Jul 12, 2024

InSilicoTrials and Axoltis to develop drugs for neurological disorders

InSilicoTrials and Axoltis to develop drugs for neurolo...

Jul 29, 2023